Featured Research

from universities, journals, and other organizations

New recommendations issued for use of cetuximab in colon cancer therapy

Date:
July 18, 2010
Source:
University of North Carolina School of Medicine
Summary:
New recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed. ongoing analysis during the clinical trial found that patients receiving the combination therapy had no significant improvement in survival compared to standard therapy.

In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed.

Related Articles


Based on earlier studies, cetuximab is now indicated for treatment of patients with advanced colorectal cancer whose tumors do not have a mutation in the KRAS gene. KRAS is one of a series of genes along a pathway that can lead tumors cells to grow, divide and evade signals that shut the cells down causing their death. Based on the results in advanced disease, researchers had hoped to see similar benefits when cetuximab was added to a standard chemotherapy regimen in earlier stages of colon cancer. However, ongoing analysis during the clinical trial found that patients receiving the combination therapy had no significant improvement in survival compared to standard therapy.

Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR) -- a cell signaling pathway that contributes to tumor growth. The drug is given by intravenous infusion for treatment of metastatic colorectal cancer and head and neck cancer. Previously, researchers found that patients with a mutated KRAS gene -- about 40 percent of those with metastatic colon cancer -- do not respond to the EGFR inhibitors currently in use.

However, the genetic test for KRAS mutation was not standard until this trial was well underway. Patients enrolled before KRAS testing were segmented from those in the rest of the study and analyzed separately, said Richard Goldberg, MD, chief of the division of hematology/oncology at the UNC-Chapel Hill School of Medicine, who presented the results for this group of patients.

"We expected that patients with the genetic mutation would not respond to cetuximab, and that is what we found," said Goldberg, who is also physician-in-chief of the N.C. Cancer Hospital.

"However, even the patients in the study whose tumors did not harbor the KRAS mutation did not benefit significantly from the combination therapy and the standard treatment proved to have the best results. We also found that the combination therapy was more toxic and the side effects of treatment -- especially in older patients -- negatively impacted their ability to complete the standard treatment," he added.

The researchers issued a recommendation that cetuximab should not be used in patients with stage III colon cancer. It remains a valuable tool in treating patients with advanced colorectal cancers whose tumors do not harbor a KRAS mutation and can either be administered as a single agent or with chemotherapy.


Story Source:

The above story is based on materials provided by University of North Carolina School of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

University of North Carolina School of Medicine. "New recommendations issued for use of cetuximab in colon cancer therapy." ScienceDaily. ScienceDaily, 18 July 2010. <www.sciencedaily.com/releases/2010/07/100716140915.htm>.
University of North Carolina School of Medicine. (2010, July 18). New recommendations issued for use of cetuximab in colon cancer therapy. ScienceDaily. Retrieved February 27, 2015 from www.sciencedaily.com/releases/2010/07/100716140915.htm
University of North Carolina School of Medicine. "New recommendations issued for use of cetuximab in colon cancer therapy." ScienceDaily. www.sciencedaily.com/releases/2010/07/100716140915.htm (accessed February 27, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, February 27, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Cherries, Snap Peas and More Tasty Spring Produce

Cherries, Snap Peas and More Tasty Spring Produce

Buzz60 (Feb. 27, 2015) From sweet cherries to sugar snap peas, spring is the peak season for some of the tastiest and healthiest produce. Krystin Goodwin (@Krystingoodwin) has the best seasonal fruits and veggies to spring in to good health! Video provided by Buzz60
Powered by NewsLook.com
New FDA-Approved Diabetes Medicine Might Save Drugmaker

New FDA-Approved Diabetes Medicine Might Save Drugmaker

Newsy (Feb. 26, 2015) The U.S. Food and Drug Administration approved new diabetes drug Toujeo on Wednesday, a move that might save French drugmaker Sanofi&apos;s profits. Video provided by Newsy
Powered by NewsLook.com
The Best Foods to Battle Stress

The Best Foods to Battle Stress

Buzz60 (Feb. 26, 2015) If you&apos;re dealing with anxiety, there are a few foods that can help. Krystin Goodwin (@krystingoodwin) has the best foods to tame stress. Video provided by Buzz60
Powered by NewsLook.com
The 5 Best Tips to Look Younger Now

The 5 Best Tips to Look Younger Now

Buzz60 (Feb. 26, 2015) Life happens, and we all get older, but forget the pricey anti-aging products and plastic surgery. You can tweak your habits to turn back the hands of time. Krystin Goodwin (@krystingoodwin) has a few simple tips to help you look and feel younger. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins